Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Pluristem Therapeutics history
Pluristem Therapeutics company history timeline
He joined Pluristem in September 2005, and redirected the Company's strategy towards cellular therapeutics to become one of the global leaders in the industry.
Yanay served in variety of executive positions in Pluristem since 2006 including Chief Financial Officer, Chief Operating Officer and Executive Vice President.
Doctor Racheli Ofir Joined Pluristem in 2007, serves as Vice President of data and intellectual property.
Lior Raviv joined Pluristem in 2011 and currently serves as Chief Technology Officer.
Doctor Halevy joined Pluristem in 2021 and serves as Chief Medical Officer.
Doctor Arthur Machlenkin joined Pluristem in May 2022 and serves as Vice president of Research.
Rate Pluristem Therapeutics' efforts to communicate its history to employees.
Pluristem Therapeutics jobs
Do you work at Pluristem Therapeutics?
Does Pluristem Therapeutics communicate its history to new hires?
Pluristem Therapeutics competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Human Genome Sciences | 1992 | $131.0M | 1,000 | - |
| Gilead Sciences | 1987 | $28.8B | 11,800 | 692 |
| Merck | 1891 | $64.2B | 74,000 | 2,290 |
| Vertex Pharmaceuticals | 1989 | $11.0B | 3,400 | 120 |
| Adverum Biotechnologies | 2006 | $3.6M | 188 | 2 |
| GlobeImmune | 1995 | $6.5M | 22 | - |
| Iovance Biotherapeutics | 2007 | $164.1M | 319 | 35 |
| Cytori Therapeutics | 1996 | $7.4M | 12 | - |
| EarlySense | 2004 | $9.5M | 175 | - |
| Cryo-Cell | 1989 | $25.4M | 98 | - |
Pluristem Therapeutics history FAQs
Zippia gives an in-depth look into the details of Pluristem Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Pluristem Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Pluristem Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Pluristem Therapeutics. The data presented on this page does not represent the view of Pluristem Therapeutics and its employees or that of Zippia.
Pluristem Therapeutics may also be known as or be related to PLURISTEM THERAPEUTICS INC, Pluristem Therapeutics, Pluristem Therapeutics Inc, Pluristem Therapeutics Inc. and Pluristem Therapeutics, Inc.